Management of Rheumatic Diseases

Introduction

• Rheumatic diseases require comprehensive management, including photoprotection, lifestyle interventions, psychosocial interventions, exercise, and physical therapy, as recommended by the European League Against Rheumatism 1

Photoprotection and Lifestyle Interventions

• The European League Against Rheumatism recommends photoprotection to prevent flares, including avoiding direct sun exposure, using physical barriers, applying broad-spectrum sunscreen, and considering vitamin D supplementation 1

Psychosocial Interventions

• The European League Against Rheumatism suggests psychosocial interventions, such as cognitive behavioral therapy, group therapy, and psychoeducational programs, to improve quality of life 1

Exercise and Physical Therapy

• Aerobic exercise is recommended to improve aerobic capacity, reduce fatigue, and alleviate depressive symptoms 1
• Hand exercises are suggested to improve mobility and function 1
• Orofacial exercises are recommended to improve mouth-related outcomes 1
• A home-based exercise program, including aerobic exercise, upper limb muscular endurance training, and hand stretching exercises, is proposed 1
• Physical therapy and exercise should be considered once acute crisis stabilizes, as it improves physical function and reduces pain, particularly beneficial for musculoskeletal manifestations 1

Patient Education and Occupational Therapy

• Patient education combined with occupational therapy is recommended to improve functional abilities 1
• Patient education and support for self-management improve quality of life, according to the Annals of the Rheumatic Diseases 1

Medications and Treatment

• Hydroxychloroquine (HCQ) is recommended as a fundamental medication for all patients with systemic autoimmune diseases, regardless of severity, according to the American College of Rheumatology 2
• Methotrexate (10-15 mg/m² BSA per week) is suggested as a second-line treatment option if the first line fails, as recommended by the European League Against Rheumatism 2
• Glucocorticoids with initial dosing of low-to-moderate doses (0.25-0.5 mg/kg/day) are recommended for musculoskeletal manifestations, targeting the lowest effective dose (≤5 mg/day) for the shortest duration possible, as recommended by the European League Against Rheumatism 3
• The American College of Obstetricians and Gynecologists recommends HCQ + low-molecular-weight heparin + low-dose aspirin in pregnant women with systemic autoimmune diseases and recurrent losses (strong recommendation) 2
• Long-term anticoagulation with warfarin is recommended for SLE patients with antiphospholipid antibodies, and direct oral anticoagulants are advised against in SLE patients with antiphospholipid syndrome, according to the American College of Rheumatology 4

Disease Assessment and Monitoring

• Disease activity should be assessed at each visit using validated indices, such as JADAS-27 or SLEDAI-2K, and organ damage should be evaluated annually, as suggested by the European League Against Rheumatism 5, 6, 7
• Laboratory monitoring should include complete blood count, anti-dsDNA antibodies, complement levels, renal function tests, and urinalysis, as recommended by the European League Against Rheumatism 5
• Annual cardiovascular risk assessment should include evaluation of blood pressure, lipid profile, blood glucose, BMI/waist circumference, and smoking status, as recommended by the European Society of Cardiology 5

Treatment of Lupus Nephritis

• The primary therapy for a lupus flare requires prompt intervention with glucocorticoids, with dosing tailored to the severity of the flare, while simultaneously initiating or adjusting immunosuppressive agents to allow for steroid tapering and prevention of future flares, as recommended by the Kidney International guideline 4
• The goal is to reduce prednisone to ≤7.5 mg/day by the end of the initial treatment phase, and continue tapering to the lowest possible dose during maintenance, as recommended by the Kidney International guideline 4
• The following table summarizes the treatment options for lupus nephritis:

• First-line options for immunosuppressive agents include Mycophenolate mofetil (MMF) at a dose of 750-1000 mg twice daily, and Mycophenolic acid at a dose of 540-720 mg twice daily, according to the Kidney International guideline 4

Pediatric SLE

• The American College of Nephrology recommends treating pediatric SLE patients with immunosuppression regimens similar to adults, with special consideration for dose adjustment, growth, fertility, and psychosocial factors specific to this population 4
• Dosage of immunosuppressive agents should be 5 mg/kg/day or 200-400 mg daily (whichever is lower) 8
• Mycophenolate mofetil (MMF) is a first-line option, with a dosage of 600 mg/m² twice daily 4, 8
• Co-management by pediatric nephrologists and rheumatologists is recommended 4

Prognosis and Outcomes

• Recent data shows survival rates without advanced CKD, kidney failure, or death of 94.2%, 92.7%, and 83.2% at 5, 10, and 20 years respectively 4
• Complete response to treatment is defined as proteinuria <0.5 g/g, with stable or improved kidney function, while partial response is defined as ≥50% reduction in proteinuria to <3 g/g, with stable kidney function 4
• Implementing a transition program for adolescents can ensure adherence and optimal outcomes 9